Chappell Todd 4

What Happened

• Todd Chappell, Chief Operating Officer of Korro Bio, received a grant of derivative securities covering 38,000 shares on Feb 2, 2026. The reported price at grant is $0.00 (no cash paid at time of grant). This is an award/compensation grant (not an open‑market purchase or sale).

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-03 (appears timely).
• Transaction type/code: Award/Grant (derivative) — reported as "A".
• Shares/units granted: 38,000; reported acquisition price: $0.00; total cash exchanged: $0.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: The award vests in 48 equal monthly installments beginning Feb 2, 2026, subject to continued service.
• No indication of immediate sale, tax withholding, or a 10b5-1 plan in the provided data.

Context

• This is a typical equity compensation grant to an executive and does not represent an open‑market buy or sell. Such awards are common for retention and incentive purposes; they only translate into actual shares or value over time as they vest and, if applicable, are exercised.